ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biotech firms join for drug linker

by Ann M. Thayer
April 25, 2016 | APPEARED IN VOLUME 94, ISSUE 17

ProBioGen has licensed Eucodis Bioscience’s technology to enzymatically link drugs to antibodies. The German contract manufacturer will offer the technology along with its antibody development services. Eucodis engineered its one-step C-LiNK enzymatic method of peptide-based, site-specific conjugation for making antibody-drug conjugates. According to Eucodis, the technology covalently links toxins or other molecules to the C-terminus of either antibody chain, without disturbing the native antibody structure and at a defined antibody-drug ratio.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment